JP2015536927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536927A5 JP2015536927A5 JP2015538467A JP2015538467A JP2015536927A5 JP 2015536927 A5 JP2015536927 A5 JP 2015536927A5 JP 2015538467 A JP2015538467 A JP 2015538467A JP 2015538467 A JP2015538467 A JP 2015538467A JP 2015536927 A5 JP2015536927 A5 JP 2015536927A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- branched
- unsubstituted
- unbranched
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719284P | 2012-10-26 | 2012-10-26 | |
| EP12382414 | 2012-10-26 | ||
| US61/719,284 | 2012-10-26 | ||
| EP12382414.6 | 2012-10-26 | ||
| PCT/EP2013/072410 WO2014064257A1 (en) | 2012-10-26 | 2013-10-25 | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536927A JP2015536927A (ja) | 2015-12-24 |
| JP2015536927A5 true JP2015536927A5 (enExample) | 2016-12-15 |
| JP6386461B2 JP6386461B2 (ja) | 2018-09-05 |
Family
ID=47148690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538467A Active JP6386461B2 (ja) | 2012-10-26 | 2013-10-25 | 特定のニューロン種へのオリゴヌクレオチド分子の選択的送達によるパーキンソン病の治療のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9084825B2 (enExample) |
| EP (1) | EP2911695B1 (enExample) |
| JP (1) | JP6386461B2 (enExample) |
| CN (1) | CN104884094A (enExample) |
| AU (1) | AU2013336581A1 (enExample) |
| CA (1) | CA2890112A1 (enExample) |
| ES (1) | ES2967530T3 (enExample) |
| HK (1) | HK1214179A1 (enExample) |
| MX (1) | MX2015005352A (enExample) |
| WO (1) | WO2014064257A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130103662A (ko) | 2010-04-19 | 2013-09-24 | 엔라이프 떼라퓨틱스, 에스.엘. | 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법 |
| EP3521451A1 (en) | 2010-11-17 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| ES2632212T3 (es) | 2011-08-04 | 2017-09-11 | Yeda Research And Development Co. Ltd. | miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina |
| WO2014064257A1 (en) | 2012-10-26 | 2014-05-01 | Nlife Therapeutics, S.L. | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
| US10125365B2 (en) | 2014-02-05 | 2018-11-13 | Yeda Research And Development Co. Ltd. | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| US10733023B1 (en) * | 2015-08-06 | 2020-08-04 | D2Iq, Inc. | Oversubscription scheduling |
| US11234995B2 (en) | 2016-01-07 | 2022-02-01 | Osaka University | α-synuclein expression inhibitor |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| US20200172903A1 (en) * | 2017-07-05 | 2020-06-04 | Osaka University | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION |
| WO2019009298A1 (ja) * | 2017-07-05 | 2019-01-10 | 国立大学法人大阪大学 | α－シヌクレイン発現抑制剤 |
| KR101890925B1 (ko) | 2017-08-08 | 2018-08-24 | 주식회사 이레산업 | 캠핑용 그릴 세트 |
| SG11202003126VA (en) * | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| US11814625B2 (en) | 2017-10-23 | 2023-11-14 | Carleton University | Aptamers as a therapeutic tool to prevent protein aggregation in neurodegenerative disease |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| WO2019140236A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| EP3737759A1 (en) | 2018-01-12 | 2020-11-18 | Roche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotides and uses thereof |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| US20220096665A1 (en) * | 2018-11-21 | 2022-03-31 | University Of Georgia Research Foundation, Inc. | Bimodal nanoparticle conjugates for non-invasive central nervous system tissue imaging |
| US20220127605A1 (en) * | 2018-11-30 | 2022-04-28 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| US12478684B2 (en) | 2019-04-11 | 2025-11-25 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
| JP7581252B2 (ja) | 2019-06-06 | 2024-11-12 | アビディティー バイオサイエンシーズ，インク． | Ｕｎａアミダイトおよびその使用 |
| EP4058807A1 (en) * | 2019-11-11 | 2022-09-21 | Oxford University Innovation Limited | Biomarkers for the prediction and identification of parkinson's disease |
| CN115168823B (zh) * | 2022-08-05 | 2025-07-18 | 聊城大学 | 基于组平均的多任务功能性近红外光谱信号的身份识别 |
| WO2024166019A1 (en) * | 2023-02-08 | 2024-08-15 | Biorchestra Co., Ltd. | Sirna targeting alpha-synuclein and uses thereof |
| AU2025205167A1 (en) * | 2024-07-09 | 2026-01-29 | China Medical University | Targeting vehicles, compositions and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL66831A0 (en) * | 1981-10-05 | 1982-12-31 | Kefalas As | Indane derivatives |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US6455736B1 (en) | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| AU1430097A (en) | 1996-01-16 | 1997-08-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| WO2005004794A2 (en) * | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| JP2007525211A (ja) * | 2004-01-19 | 2007-09-06 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | パーキンソン病の診断検査 |
| WO2007050789A2 (en) * | 2005-10-25 | 2007-05-03 | Nëdken Corporation | Glycosyl-oligonucleotide conjugates and methods |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| EP2235175A4 (en) | 2007-12-20 | 2012-04-25 | Angiochem Inc | POLYPEPTIDE NUCLEIC ACID CONJUGATES AND USES THEREOF |
| WO2010129791A1 (en) * | 2009-05-06 | 2010-11-11 | University Of Medicine And Dentistry Of New Jersey | Rna targeting in alpha-synucleinopathies |
| WO2011087804A2 (en) | 2009-12-21 | 2011-07-21 | Medtronic, Inc. | Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
| KR20130103662A (ko) | 2010-04-19 | 2013-09-24 | 엔라이프 떼라퓨틱스, 에스.엘. | 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법 |
| WO2012027713A2 (en) | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| EP3521451A1 (en) * | 2010-11-17 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| MX2015005328A (es) | 2012-10-26 | 2015-09-25 | Nlife Therapeutics S L | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. |
| WO2014064257A1 (en) | 2012-10-26 | 2014-05-01 | Nlife Therapeutics, S.L. | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
-
2013
- 2013-10-25 WO PCT/EP2013/072410 patent/WO2014064257A1/en not_active Ceased
- 2013-10-25 HK HK16102420.8A patent/HK1214179A1/zh unknown
- 2013-10-25 MX MX2015005352A patent/MX2015005352A/es unknown
- 2013-10-25 CN CN201380068146.3A patent/CN104884094A/zh active Pending
- 2013-10-25 CA CA2890112A patent/CA2890112A1/en not_active Abandoned
- 2013-10-25 ES ES13783061T patent/ES2967530T3/es active Active
- 2013-10-25 AU AU2013336581A patent/AU2013336581A1/en not_active Abandoned
- 2013-10-25 EP EP13783061.8A patent/EP2911695B1/en active Active
- 2013-10-25 JP JP2015538467A patent/JP6386461B2/ja active Active
- 2013-10-28 US US14/065,024 patent/US9084825B2/en active Active - Reinstated
-
2015
- 2015-07-20 US US14/803,811 patent/US10125363B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP6440170B2 (ja) | キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤 | |
| BR112020007881A2 (pt) | Oligômeros anti-senso para o tratamento de condições e doenças baseadas no decaimento de rna mediado por nonsense | |
| CA2921459A1 (en) | Oligonucleotides targeting euchromatin regions of genes | |
| JP2014527401A5 (enExample) | ||
| DK3218488T3 (en) | ANTISENSE OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNAL | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2012034693A5 (enExample) | ||
| AU2009222442B2 (en) | Pharmaceutical composition | |
| RU2015104762A (ru) | Хиральный контроль | |
| JP2015523854A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| HRP20160261T1 (hr) | Komplementarni antagonisti i njihova uporaba | |
| BR112014018427B1 (pt) | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker | |
| HRP20160025T1 (hr) | Sredstva i metode za rješavanje mišiä†nih poremeä†aja | |
| JP2014509511A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| JP2013226147A5 (enExample) | ||
| HK1209781A1 (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif | |
| JP2009514877A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| CA2921457A1 (en) | Heterochromatin forming non-coding rnas | |
| JP2023500661A5 (enExample) | ||
| JP2014508161A5 (enExample) |